The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 1995

Filed:

Oct. 08, 1993
Applicant:
Inventors:

Reinhard Bredehorst, Washington, DC (US);

Chong-Ho Kim, Rockville, MD (US);

Richard McCabe, Rockville, MD (US);

Nicholas Pomato, Frederick, MD (US);

Carl-Wilhelm Vogel, Washington, DC (US);

Assignee:

Akzo N.V., Arnhem, NL;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K / ; A61K / ; C12N / ; C07H / ;
U.S. Cl.
CPC ...
424 943 ; 424 9461 ; 53038815 ; 514 34 ; 514 55 ; 536 20 ; 536-64 ; 435177 ;
Abstract

A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.


Find Patent Forward Citations

Loading…